Breast Cancer | Clinical

September 27, 2022

Clinicians use their knowledge of emerging subtypes and biomarkers, which provide a hint at possible outcomes, to select therapy from among the ever-increasing treatment armamentarium.

September 25, 2022

During a Targeted Oncology case-based roundtable event, Erika P. Hamilton, MD, discussed the choice of first- and second-line therapy for a patient with triple-negative breast cancer following adjuvant chemotherapy.

September 20, 2022

William J. Gradishar, MD, discusses the questions ongoing studies are looking to answer in the breast cancer space.

September 19, 2022

Nearly all patients with HR-positive breast cancer are treated with endocrine therapy, yet Black women are 4 times more likely to die of this disease compared with White women.

September 16, 2022

A patient with estrogen receptor positive, HER2-negative metastatic breast cancer enrolled in the phase 2 ELAINE 1 trial demonstrated a durable complete response when treated with lasofoxifene.

September 12, 2022

Ribociclib combined with endocrine therapy adds survival benefit when given to patients with hormone receptor–positive/HER2-negative advanced breast cancer with visceral metastases.

September 12, 2022

Pembrolizumab in the neoadjuvant and adjuvant settings demonstrated similar health-related quality-of-life scores in patients with triple-negative breast cancer when compared with placebo.

September 11, 2022

Patient-reported outcomes from the DESTINY-Breast04 trial showed a quality-of-life benefit from treatment with trastuzumab deruxtecan compared with physician’s choice of therapy in patients with hormone receptor–positive, HER2-low metastatic breast cancer.

September 11, 2022

The AMEERA-3 trial failed to meet its primary end point of superior progression-free survival for amcenestrant compared with endocrine therapy in patients with endocrine-resistant, ER-positive advanced breast cancer.

September 10, 2022

The antibody-drug conjugate sacituzumab govitecan demonstrated superior overall response rate and progression-free survival in patients with breast cancer with limited options due to lack of high HER2 expression.